Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515524 · ClinicalTrials.gov registry record
Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
A clinical trial of Retinopathy of Prematurity, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 100
- Enrollment target
- 20
- Study locations
NCT04515524 is a study of Retinopathy of Prematurity that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 100 participants, below the 355-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04515524, a study of Retinopathy of Prematurity, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary objectives of the study are: * To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). * To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. Secondary objectives of the study are: * To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. * To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.
Conditions Studied
Interventions
- OTHER Non-Interventional
Study Locations (20)
Other
- Acibadem City Clinic Multiprofile Hospital for Active Treatment - Sofia
- Specialized Hospital for Active Treatment of Eye Diseases - Varna - Varna
- SC Centrul Medical Unirea SRL - Iași
- St. Petersburg State Pediatric Medical University - ophtalmology - Saint Petersburg
- Chung-Ho Memorial Hospital - Kaohsiung City
California
- UCSD Shiley Eye Institute, Jacobs Retina Center - La Jolla
- Loma Linda University Eye Institute - Loma Linda
- University of California San Francisco - Ophthalmology - San Francisco
New York
- New York University School of Medicine - Oncology - New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Rhode Island
- Lifespan - Women & Infants Hospital of RI - Providence
Texas
- The Children's Hospital of San Antonio - San Antonio
West Virginia
- West Virginia University - Morgantown
Antioquia
- Clinica Universitaria Bolivariana - Medellín
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2026-11-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04515524
The ClinicalTrials.gov registry entry for NCT04515524 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 355-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (72% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinopathy of Prematurity appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional is the first listed.
NCT04515524 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04515524 about?
NCT04515524 is a clinical study titled "Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)". Primary objectives of the study are: * To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). * To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for ...
What is the current status of trial NCT04515524?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2021-02-05. Estimated completion is 2026-11-05.
What conditions does trial NCT04515524 study?
This clinical trial studies the following conditions: Retinopathy of Prematurity.
What interventions are being tested in trial NCT04515524?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT04515524?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04515524 being conducted?
This trial has 20 study locations across California, New York, Ohio, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinopathy of Prematurity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Retinal Vasculature in Infant Eyes
RECRUITING
-
Clinical and Genetic Analysis of ROP
RECRUITING
-
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
RECRUITING · NA
-
Bevacizumab Treatment For Type 1 ROP
ACTIVE NOT RECRUITING · Phase 2
-
Validation of i-ROP DL to Detect More Than Mild ROP
ACTIVE NOT RECRUITING · NA
-
The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.